Loading...
Market
Will Cassava Sciences' stock price drop below $20 by the end of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock price data from NASDAQ
Story
Cassava Sciences, Founder, and CUNY Scientist Settle SEC Charges Over Alzheimer's Data Manipulation
Sep 26, 2024, 10:53 PM
Cassava Sciences Inc. (NASDAQ: SAVA) and two former executives have settled with the Securities and Exchange Commission (SEC) for $40 million over charges of misleading claims regarding their Alzheimer's clinical trial. The SEC alleges that the company falsified data from their Phase 2b trial, which showed no measurable cognitive improvement in patients' episodic memory. Key figures involved include founder Remi Barbier, his wife Lindsay Burns, and Dr. Wang of the City University of New York (CUNY), who were charged with manipulating research results. Despite these allegations, Cassava Sciences maintains a market valuation of $1.5 billion, and its stock performance remains strong over the past one, two, and five years.
View original story
Similar markets
Yes • 50%
No • 50%
Stock price above $50 • 25%
Stock price between $20 and $50 • 25%
Stock price between $5 and $20 • 25%
Stock price below $5 • 25%
Above $50 • 25%
$30 to $50 • 25%
$10 to $30 • 25%
Below $10 • 25%
Outperforms • 33%
Performs similarly • 34%
Underperforms • 33%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Revenue increases by 10% or more • 25%
Revenue stays within 10% of current levels • 25%
Revenue decreases by 10% or more • 25%
Cassava Sciences reports a loss • 25%
Profitable • 25%
Break-even • 25%
Loss-making but stable • 25%
Facing financial distress • 25%